Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Intangibles (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Intangibles for 5 consecutive years, with $370000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Intangibles fell 11.9% to $370000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $370000.0, a 11.9% decrease, with the full-year FY2024 number at $370000.0, down 11.9% from a year prior.
  • Intangibles was $370000.0 for Q4 2024 at Vivos Therapeutics, down from $408000.0 in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $2.5 million in Q2 2021 to a low of $270000.0 in Q4 2020.
  • A 5-year average of $548069.5 and a median of $341000.0 in 2021 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: plummeted 87.22% in 2022, then soared 39.07% in 2023.
  • Vivos Therapeutics' Intangibles stood at $270000.0 in 2020, then increased by 26.3% to $341000.0 in 2021, then fell by 11.44% to $302000.0 in 2022, then skyrocketed by 39.07% to $420000.0 in 2023, then fell by 11.9% to $370000.0 in 2024.
  • Per Business Quant, the three most recent readings for VVOS's Intangibles are $370000.0 (Q4 2024), $408000.0 (Q1 2024), and $420000.0 (Q4 2023).